VELETRI Market Demand Forecast and Leading Players Analysis Through 2030

 The Business Research Company’s 2026 market reports introduce new features such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, all designed to enhance the depth, usability, and strategic value of the insights provided.

What Is the Forecast Market Size and Growth Rate of the VELETRI Market?
The veletri market size has grown strongly in recent years. It will grow from $1.45 billion in 2025 to $1.56 billion in 2026 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to clinical efficacy of epoprostenol, rising diagnosis of pah, hospital reliance on iv prostacyclins, limited oral alternatives, improved pah survival rates.

The veletri market size is expected to see strong growth in the next few years. It will grow to $2.07 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to increasing pah prevalence, growth in specialty pah centers, rising demand for stable formulations, expansion of infusion therapy adoption, increased awareness of pah. Major trends in the forecast period include growing adoption of non-refrigerated prostacyclin therapies, increased use of continuous infusion pah treatments, rising demand for advanced pah vasodilators, expansion of hospital-based pah management, increased focus on improving pah patient mobility.

Claim your free report sample now:
https://www.thebusinessresearchcompany.com/report/veletri-global-market-report

What Are the Key Growth Factors Supporting the VELETRI Market Expansion?
The increasing prevalence of venous diseases is expected to propel the growth of the VELETRI market going forward. Venous diseases are conditions where the veins have impaired blood flow, causing swelling, pain, and possible complications like varicose veins and deep vein thrombosis. The increasing prevalence of venous diseases is driven by factors such as an aging population, sedentary lifestyles, obesity, and improved diagnostic capabilities. Veletri is used to improve exercise capacity and reduce symptoms in patients with venous diseases affecting the pulmonary vasculature. For instance, in January 2025, according to the Centers for Disease Control and Prevention, a US-based government organization, each year, up to 900,000 individuals in the United States are impacted by venous thromboembolism (VTE), a condition characterized by blood clots, with an estimated 60,000 to 100,000 fatalities attributed to VTE annually. Therefore, the increasing prevalence of venous diseases is driving the growth of the VELETRI market.

What Are the Emerging Segments in the VELETRI Market?
The veletri market covered in this report is segmented –

1) By Formulation Stability Type: Room-Temperature Stable Formulation, Refrigeration-Required Formulation
2) By Treatment Setting: Hospitals, Specialized Pulmonary Hypertension Centers
3) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies

Subsegments:
1) By Room-Temperature Stable Formulation: Ready-to-Use Formulation, Extended Stability Infusion Solution
2) By Refrigeration-Required Formulation: Reconstituted Cold-Chain Formulation, Limited-Stability Infusion Solution

What Are the Key Trends Shaping the VELETRI Market?
Major companies operating in the Veletri market are focusing on expanding access via generic formulations, such as FDA-approved epoprostenol sodium injection, to provide cost-effective treatment options for pulmonary arterial hypertension patients. Generic Veletri refers to therapeutically equivalent versions of the branded epoprostenol product that meet FDA standards for quality, safety, and efficacy, offering the same clinical benefits at a lower cost. For instance, in October 2025, Mylan Pharmaceuticals, a US-based pharmaceutical company, received FDA approval for its generic Veletri (epoprostenol sodium) injection. The product is supplied in multiple vial strengths, including 20 mg/20 mL, 50 mg/20 mL, 100 mg/20 mL, and 200 mg/20 mL, and provides the same prostacyclin mimetic activity as the branded version, helping improve exercise tolerance and manage symptoms in PAH patients.

Who Are the Industry Leaders in the VELETRI Market?
Major companies operating in the veletri market are Johnson & Johnson, Bayer Pharma AG, Novartis AG, GlaxoSmithKline plc, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Sandoz International GmbH, Sun United Therapeutics Corporation, Actelion Pharmaceuticals Ltd., Bayer Pharma AG, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Johnson & Johnson, Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Euroapi S.A., Pfizer CentreOne, Sai Life Sciences Limited, Zhejiang Ausun Pharmaceutical Co. Ltd., Yonsung Fine Chemicals Co. Ltd., Cayman Pharma S.r.o., Nichi-Iko Pharmaceutical Co. Ltd., Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Ltd., Hikma Pharmaceuticals plc

Get the full veletri market report here:
https://www.thebusinessresearchcompany.com/report/veletri-global-market-report

Which Region Is Projected to Account for the Largest Share of the VELETRI Market?
North America was the largest region in the VELETRI market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the veletri market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Contact Us:

The Business Research Company: Global Market Research Reports & Consulting | The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info

Follow Us On:

LinkedIn: The Business Research Company | LinkedIn